Biomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica, Inc. announced third quarter fiscal 2026 financial results showcasing strong clinical data for their inFoods® IBS diagnostic product, securing a $300 national Medicare payment rate, and significant European market progress with hp+detect™ gaining UK regulatory registration and first commercial orders. While overall revenues slightly decl…